These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

343 related articles for article (PubMed ID: 15868406)

  • 1. Congenital muscular dystrophy: molecular and cellular aspects.
    Jimenez-Mallebrera C; Brown SC; Sewry CA; Muntoni F
    Cell Mol Life Sci; 2005 Apr; 62(7-8):809-23. PubMed ID: 15868406
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Mutations in the human LARGE gene cause MDC1D, a novel form of congenital muscular dystrophy with severe mental retardation and abnormal glycosylation of alpha-dystroglycan.
    Longman C; Brockington M; Torelli S; Jimenez-Mallebrera C; Kennedy C; Khalil N; Feng L; Saran RK; Voit T; Merlini L; Sewry CA; Brown SC; Muntoni F
    Hum Mol Genet; 2003 Nov; 12(21):2853-61. PubMed ID: 12966029
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Congenital muscular dystrophy with glycosylation defects of alpha-dystroglycan in Japan.
    Matsumoto H; Hayashi YK; Kim DS; Ogawa M; Murakami T; Noguchi S; Nonaka I; Nakazawa T; Matsuo T; Futagami S; Campbell KP; Nishino I
    Neuromuscul Disord; 2005 May; 15(5):342-8. PubMed ID: 15833426
    [TBL] [Abstract][Full Text] [Related]  

  • 4. [Fukuyama congenital muscular dystrophy and related alpha-dystroglycanopathies].
    Murakami T; Nishino I
    Brain Nerve; 2008 Oct; 60(10):1159-64. PubMed ID: 18975603
    [TBL] [Abstract][Full Text] [Related]  

  • 5. 'Congenital muscular dystrophy caused by integrin alpha7 deficiency'.
    Nakashima H; Kibe T; Yokochi K
    Dev Med Child Neurol; 2009 Mar; 51(3):245. PubMed ID: 19260934
    [No Abstract]   [Full Text] [Related]  

  • 6. Milder phenotype of congenital muscular dystrophy in a novel POMT1 mutation.
    Al-Zaidy SA; Baskin B; Hawkins C; Yoon G; Ray PN; Vajsar J
    Muscle Nerve; 2012 May; 45(5):752-5. PubMed ID: 22499106
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Muscular dystrophies: an update on pathology and diagnosis.
    Sewry CA
    Acta Neuropathol; 2010 Sep; 120(3):343-58. PubMed ID: 20652576
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Telethonin-deficiency initially presenting as a congenital muscular dystrophy.
    Ferreiro A; Mezmezian M; Olivé M; Herlicoviez D; Fardeau M; Richard P; Romero NB
    Neuromuscul Disord; 2011 Jun; 21(6):433-8. PubMed ID: 21530252
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [Alpha-dystroglycanopathy (FCMD, MEB, etc): abnormal glycosylation and muscular dystrophy].
    Toda T
    Rinsho Shinkeigaku; 2005 Nov; 45(11):932-4. PubMed ID: 16447766
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Diagnosis and etiology of congenital muscular dystrophy.
    Peat RA; Smith JM; Compton AG; Baker NL; Pace RA; Burkin DJ; Kaufman SJ; Lamandé SR; North KN
    Neurology; 2008 Jul; 71(5):312-21. PubMed ID: 18160674
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Expression profiling of muscles from Fukuyama-type congenital muscular dystrophy and laminin-alpha 2 deficient congenital muscular dystrophy; is congenital muscular dystrophy a primary fibrotic disease?
    Taniguchi M; Kurahashi H; Noguchi S; Sese J; Okinaga T; Tsukahara T; Guicheney P; Ozono K; Nishino I; Morishita S; Toda T
    Biochem Biophys Res Commun; 2006 Apr; 342(2):489-502. PubMed ID: 16487936
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Aberrant neuromuscular junctions and delayed terminal muscle fiber maturation in alpha-dystroglycanopathies.
    Taniguchi M; Kurahashi H; Noguchi S; Fukudome T; Okinaga T; Tsukahara T; Tajima Y; Ozono K; Nishino I; Nonaka I; Toda T
    Hum Mol Genet; 2006 Apr; 15(8):1279-89. PubMed ID: 16531417
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [Updates in muscular dystrophies].
    Erazo-Torricelli R
    Rev Neurol; 2004 Nov 1-15; 39(9):860-71. PubMed ID: 15543503
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The congenital muscular dystrophies in 2004: a century of exciting progress.
    Muntoni F; Voit T
    Neuromuscul Disord; 2004 Oct; 14(10):635-49. PubMed ID: 15351421
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Immunocytochemical analysis of human muscular dystrophy.
    Sewry CA
    Microsc Res Tech; 2000 Feb 1-15; 48(3-4):142-54. PubMed ID: 10679962
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Dystroglycan and muscular dystrophies related to the dystrophin-glycoprotein complex.
    Sciandra F; Bozzi M; Bianchi M; Pavoni E; Giardina B; Brancaccio A
    Ann Ist Super Sanita; 2003; 39(2):173-81. PubMed ID: 14587215
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [Fukuyama-type congenital muscular dystrophy and alpha-dystroglycanopathy].
    Kobayashi K; Toda T
    Tanpakushitsu Kakusan Koso; 2004 Nov; 49(15 Suppl):2457-62. PubMed ID: 15553001
    [No Abstract]   [Full Text] [Related]  

  • 18. Subcellular localization of fukutin and fukutin-related protein in muscle cells.
    Matsumoto H; Noguchi S; Sugie K; Ogawa M; Murayama K; Hayashi YK; Nishino I
    J Biochem; 2004 Jun; 135(6):709-12. PubMed ID: 15213246
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Glycomarkers for muscular dystrophy.
    Hewitt JE
    Biochem Soc Trans; 2011 Jan; 39(1):336-9. PubMed ID: 21265799
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Laminin alpha1 chain mediated reduction of laminin alpha2 chain deficient muscular dystrophy involves integrin alpha7beta1 and dystroglycan.
    Gawlik KI; Mayer U; Blomberg K; Sonnenberg A; Ekblom P; Durbeej M
    FEBS Lett; 2006 Mar; 580(7):1759-65. PubMed ID: 16504180
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 18.